<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-419 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-419</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-419</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-7.html">extraction-schema-7</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of population differences in the prevalence of activating EGFR mutations in lung cancer and proposed reasons for higher frequency in East Asians. Include quantitative evidence about mutation frequencies by ancestry, smoking status, sex, and age; germline variants and their allele frequencies/associations; environmental and hormonal exposures; mutational signatures and tumor mutation burden; co-mutation patterns; and differential response to EGFR-TKIs by ethnicity. Capture study design, methods, and any counter-evidence or limitations.</div>
                <p><strong>Paper ID:</strong> paper-164502a687f04effb4ac5dadbdd9d806fde4264c</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/164502a687f04effb4ac5dadbdd9d806fde4264c" target="_blank">Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Clinical Oncology</p>
                <p><strong>Paper TL;DR:</strong> This study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers and indicates that prospective mutation testing in these patients should successfully assign a targeted therapy in the majority of cases.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e419.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e419.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of population differences in the prevalence of activating EGFR mutations in lung cancer and proposed reasons for higher frequency in East Asians. Include quantitative evidence about mutation frequencies by ancestry, smoking status, sex, and age; germline variants and their allele frequencies/associations; environmental and hormonal exposures; mutational signatures and tumor mutation burden; co-mutation patterns; and differential response to EGFR-TKIs by ethnicity. Capture study design, methods, and any counter-evidence or limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Sun2010_EAS_never-smokers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A single-institution surgical sequencing cohort of 52 resected lung adenocarcinomas from Chinese never-smokers reporting comprehensive targeted sequencing for recurrent driver mutations, showing a very high prevalence of activating EGFR kinase domain mutations and a characteristic co-mutation pattern (PIK3CA co-occurrence, mutual exclusivity among other drivers).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_identifier</strong></td>
                            <td>DOI: 10.1200/JCO.2010.29.6038</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>publication_year</strong></td>
                            <td>2010</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Surgical targeted-sequencing cohort (consecutive resected tumors; multiplex PCR/sequencing for targeted exons and fusion PCR for ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_context</strong></td>
                            <td>China (Shanghai Cancer Hospital, Fudan University) — single institution; all patients Chinese (East Asian)</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_histology</strong></td>
                            <td>Pulmonary adenocarcinoma (resected)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_tumor</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry_groups</strong></td>
                            <td>East Asian (Chinese) only; ancestry/self-report: all patients were Chinese (100%); no other ancestry groups compared in this study</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency_overall</strong></td>
                            <td>78.8% (41 of 52 tumors; 95% CI 0.6580 to 0.8792) — activating EGFR kinase-domain mutations (exons 18-21) as assayed in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency_by_group</strong></td>
                            <td>By sex (within this East Asian never-smoker cohort): Females: 82.9% (34/41 female patients had EGFR mutations among 41 female patients? — text: 'Eighty-two point nine percent of tumors (34 of 41) from female never-smokers harbored an EGFR kinase domain mutation'); Males: 63.6% (7 of 11 male never-smokers). Smoking status: all patients were never-smokers (<100 cigarettes lifetime). Age: mean age overall 59.04 years; mean age for EGFR-mutant cases 59.10 years (no stratified mutation frequencies by age groups reported). Exact breakdowns reported: overall 41 EGFR-mutant tumors (78.8% of 52); 21 exon 19 deletions and 18 L858R among the 41 mutated tumors (see subtype field).</td>
                        </tr>
                        <tr>
                            <td><strong>effect_size_ethnic_difference</strong></td>
                            <td>No numerical effect size (OR/RR/HR) for ethnic/ancestry differences reported in this paper — the study includes only East Asian (Chinese) patients and cites prior literature noting ethnicity as associated with EGFR mutation enrichment but does not report adjusted models or comparative effect sizes.</td>
                        </tr>
                        <tr>
                            <td><strong>difference_persists_in_never_smokers</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>difference_persists_after_adjustment</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_subtypes_distribution</strong></td>
                            <td>Among the 41 EGFR-mutant tumors: exon 19 deletions = 21/41 (51.2% of EGFR-mutants; 21/52 = 40.4% of all tumors), L858R = 18/41 (43.9% of EGFR-mutants; 18/52 = 34.6% of all tumors), other alterations = 2/41 (4.9% of EGFR-mutants; 2/52 = 3.8% of all tumors) — the two others were an exon 20 insertion and a double mutation involving exon 18 (G719S) + exon 21 (L861Q). No T790M germline or somatic baseline T790M detected in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>co_mutation_landscape</strong></td>
                            <td>PIK3CA mutations in 4 of 52 tumors (7.7%); all four PIK3CA mutations co-occurred with EGFR mutations (co-occurrence). TP53 mutations found in 15 of 52 tumors (28.8%). KRAS mutation found in 1 of 52 (1.9%). HER2 kinase-domain insertions in 2 of 52 (3.8%). EML4-ALK fusions in 3 of 52 (5.8%). BRAF, NRAS, HRAS, and LKB1 mutations were not detected. Driver alterations (EGFR, HER2, KRAS, ALK) were mutually exclusive in this cohort; PIK3CA and TP53 could co-occur with EGFR.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_spectrum</strong></td>
                            <td>Not reported (no TMB values or base-substitution spectrum analyses provided).</td>
                        </tr>
                        <tr>
                            <td><strong>mutational_signatures</strong></td>
                            <td>Not reported (no COSMIC signatures or signature decomposition presented).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_exposures_assessed</strong></td>
                            <td>Not assessed in this study. The paper cites prior epidemiologic work linking never-smoking status and lower pack-years to higher EGFR mutation likelihood (reference 9) and references broader literature on environmental risk factors in never-smokers, but does not measure or report data on cooking oil fumes, indoor coal burning, PM2.5, radon, secondhand smoke, occupational exposures, or other exposures in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>hormonal_factors</strong></td>
                            <td>Not evaluated in this study; no data on estrogen exposure, hormone replacement therapy, or ER expression with respect to EGFR mutation prevalence were presented.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_variants_and_haplotypes</strong></td>
                            <td>This study does not report germline SNP/haplotype association data or allele frequencies. The authors note in the text that T790M is 'rarely in never-smoking patients with lung cancer as a rare germline variant' (reference 14), but provide no allele frequencies or germline association analyses in their cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>inherited_egfr_pathogenic_variants</strong></td>
                            <td>Only a literature mention: germline EGFR T790M has been reported rarely (cited), but no germline pathogenic EGFR variants were identified or quantified in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>Not investigated or reported in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>testing_or_selection_bias</strong></td>
                            <td>Potential selection biases: single-institution surgical series (resected tumors only) collected consecutively but subset of 52 chosen by inclusion criteria (minimum 70% tumor cells, availability of sufficient tissue, never-smoking status, no neoadjuvant therapy, and corresponding normal tissue available), which may bias toward earlier-stage, resectable cases and toward specimens amenable to molecular analysis. All patients were Chinese; no multi-ethnic comparison. Authors acknowledge sample-size limitations for some observations (eg, PIK3CA).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_tki_response_by_ethnicity</strong></td>
                            <td>The paper cites prior clinical trial data: IPASS (Pan-Asian) results reported overall objective radiographic response to gefitinib = 43% (all treated patients), and among patients with known EGFR mutations response rate = 71.2% (references cited). The paper also cites WJTOG3405 (in EGFR-mutant patients) reported response ~62.1% and mentions similar results observed with erlotinib in white never-smokers (reference 11), but this study itself does not include TKI treatment outcomes stratified by ethnicity or provide adjusted comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>methods_key_details</strong></td>
                            <td>Tumor and matched normal tissue snap-frozen; DNA and RNA extracted using Qiagen kits; cDNA synthesized from RNA. EGFR exons 18-22, HER2 exons 18-21, KRAS exons 2-3, BRAF exons 11-15 amplified using cDNA for sequencing; TP53 and LKB1 all exons and PIK3CA exons 9 and 20 sequenced from genomic DNA. ALK fusions detected by multiplex PCR using cDNA with primers designed to amplify known EML4-ALK variants; PCR program and polymerase reported. Products directly sequenced in forward and reverse directions; all mutations verified by independent PCR isolate. Statistical tests: chi-square and Fisher's exact tests (SPSS 16.0); P values two-sided.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>The authors' main interpretive suggestion is that lung adenocarcinoma from East Asian never-smokers is molecularly defined predominantly by targetable mutant kinases (EGFR, HER2, ALK), implying etiologic pathways in this clinical subgroup differ from smoking-related tumors; they propose that these high EGFR mutation rates likely underlie the clinical sensitivity seen in East Asian and never-smoking patients to EGFR-TKIs. They note co-occurring PIK3CA mutations and exon 20 insertions may underlie primary resistance in subsets but do not propose specific inherited or environmental mechanisms explaining higher East Asian prevalence.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_null_results</strong></td>
                            <td>The paper does not present direct counter-evidence to the East-Asian enrichment hypothesis but notes that EGFR-mutant tumors are also found in non-Asian never-smokers (citing erlotinib responses in white never-smokers) and that some previously reported mutation frequencies (eg, PIK3CA) differ from prior studies. They found no BRAF, NRAS, HRAS, or LKB1 mutations in this cohort (contrasting frequencies in other ethnicities reported in literature).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_conflicts</strong></td>
                            <td>Limitations: modest sample size (n=52), single-center surgical series (selection for resectable disease), lack of non-Asian comparison group, no germline or environmental exposure data, no TMB or mutational-signature analysis, limited power for subgroup comparisons. Conflicts/funding: disclosures include William Pao receiving research funding and consultant roles with industry and having a licensed EGFR T790M patent; study funding from Chinese national and Shanghai city grants and US NCI grants (detailed in manuscript disclosures).</td>
                        </tr>
                        <tr>
                            <td><strong>notable_quotes</strong></td>
                            <td>1) Introduction: "retrospective studies showed that never-smoking status, along with adenocarcinoma histology and East Asian ethnicity, were associated with a higher likelihood of responding to treatment." (INTRODUCTION). 2) Results (EGFR Mutation Status): "Seventy-eight point eight percent of tumors (41 of 52; 95% CI, 0.6580 to 0.8792) were found to harbor EGFR kinase domain mutations." (RESULTS, EGFR Mutation Status).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy <em>(Rating: 2)</em></li>
                <li>Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas <em>(Rating: 2)</em></li>
                <li>Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: A preliminary report <em>(Rating: 2)</em></li>
                <li>Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications <em>(Rating: 2)</em></li>
                <li>Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients <em>(Rating: 1)</em></li>
                <li>Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>